These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 25534522)

  • 1. [Impact of a regional pharmacovigilance network on notification of adverse drug reactions: results at 3 years].
    Picard S; Polard E; Oger E; Bellissant E
    Therapie; 2015; 70(3):293-9. PubMed ID: 25534522
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Online reporting of adverse drug reactions: a study from a French regional pharmacovigilance center.
    Abadie D; Chebane L; Bert M; Durrieu G; Montastruc JL
    Therapie; 2014; 69(5):395-400. PubMed ID: 25269141
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adverse drug reactions' reporting in a Mexican hospital.
    Valdez-Ramírez LA; Serrano-Medina A; Cornejo-Bravo JM
    Int J Pharm Pract; 2020 Dec; 28(6):660-662. PubMed ID: 32476179
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A survey of spontaneous reporting of adverse drug reactions in 10 years of activity in a pharmacovigilance centre in Portugal.
    Marques J; Ribeiro-Vaz I; Pereira AC; Polónia J
    Int J Pharm Pract; 2014 Aug; 22(4):275-82. PubMed ID: 24188533
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Comparative relevance of declaration of side effects by patients and health professionals].
    Lagneau A; Vigier C; Marianna A; Serfaty R; Rocher F; Spreux A; Drici MD
    Therapie; 2017 Dec; 72(6):625-633. PubMed ID: 28780021
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinical pharmacy and pharmacovigilance over a period of nine years in hospital].
    Guédat MG; Gouraud A; Ramiah T; Demazière J; Delanoy B; Vial T; Leboucher G; Charpiat B
    Therapie; 2012; 67(3):243-50. PubMed ID: 22874491
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Adverse drug reactions in pediatrics: Experience of a regional pharmacovigilance center].
    Saint-Martin C; Kanagaratnam L; de Boissieu P; Azzouz B; Abou Taam M; Trenque T
    Therapie; 2016 Oct; 71(5):467-473. PubMed ID: 27203165
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cyberpharmacovigilance: What is the usefulness of the social networks in pharmacovigilance?
    Bagheri H; Lacroix I; Guitton E; Damase-Michel C; Montastruc JL
    Therapie; 2016 Apr; 71(2):235-9. PubMed ID: 27080844
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Direct reporting by patients of adverse drug reactions in Spain].
    Esther Salgueiro M; Jimeno FJ; Aguirre C; García M; Ordóñez L; Manso G
    Farm Hosp; 2013; 37(1):65-71. PubMed ID: 23461502
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adverse drug reactions reporting in Calabria (Southern Italy) in the four-year period 2011-2014: impact of a regional pharmacovigilance project in light of the new European Legislation.
    Leporini C; Marrazzo G; Mumoli L; Esposito S; Gallelli L; Mangano G; Brancati G; De Francesco EA; Russo E; De Sarro G;
    Expert Opin Drug Saf; 2017 May; 16(5):515-522. PubMed ID: 28395523
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ten years of pharmacovigilance in Italy: the experience of Emilia-Romagna region in the monitoring of drug's safety profile.
    Motola D; Melis M; Lo Bianco S; Buccellato E; Biagi C; Vaccheri A
    Expert Opin Drug Saf; 2014 Jul; 13(7):867-73. PubMed ID: 24809453
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The reorganisation of European pharmacovigilance. Part 2. From spontaneous reports to agency reviews and decisions.
    Prescrire Int; 2015 Feb; 24(157):50-4. PubMed ID: 25802924
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Assessment of an active pharmacovigilance system carried out by a pharmacist].
    Sánchez I; Amador C; Plaza JC; Correa G; Amador R
    Rev Med Chil; 2014 Aug; 142(8):998-1005. PubMed ID: 25424672
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adverse drug reactions in neonates: could we be documenting more?
    Hawcutt DB; O'Connor O; Turner MA
    Expert Rev Clin Pharmacol; 2014 Nov; 7(6):807-20. PubMed ID: 25225053
    [TBL] [Abstract][Full Text] [Related]  

  • 15. French pharmacovigilance: Missions, organization and perspectives.
    Vial T
    Therapie; 2016 Apr; 71(2):143-50. PubMed ID: 27080832
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drugs and Sleep Apneas? A review of the French Pharmacovigilance database.
    Linselle M; Montastruc F; Jantzen H; Valnet-Rabier MB; Haramburu F; Coquerel A; Gouraud A; Perault-Pochat MC; Bagheri H; Montastruc JL
    Therapie; 2015; 70(4):347-50. PubMed ID: 25679185
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacovigilance in resource-limited countries.
    Olsson S; Pal SN; Dodoo A
    Expert Rev Clin Pharmacol; 2015; 8(4):449-60. PubMed ID: 26041035
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Improving adverse drug reaction reporting by general practitioners through clinical research assistants visits].
    Durrieu G; Jacquot J; Baudrin D; Mège M; Rousseau V; Bagheri H; Bondon-Guitton E; Abadie D; Montastruc F; Bismuth M; Oustric S; Montastruc JL
    Therapie; 2017 Jun; 72(3):351-355. PubMed ID: 27865436
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Pharmacovigiance: The spontaneous reporting system in Switzerland].
    Schäublin M
    Ther Umsch; 2015 Dec; 72(11-12):743-8. PubMed ID: 26654819
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Encouraging spontaneous reporting of adverse effects.
    Prescrire Int; 2015 Feb; 24(157):53. PubMed ID: 25802925
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.